Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Purchases 1,500 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Rating) CEO Snehal Patel purchased 1,500 shares of the company’s stock in a transaction on Friday, January 20th. The stock was acquired at an average cost of $17.37 per share, for a total transaction of $26,055.00. Following the completion of the purchase, the chief executive officer now owns 2,732,886 shares of the company’s stock, valued at approximately $47,470,229.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Snehal Patel also recently made the following trade(s):

  • On Friday, January 6th, Snehal Patel purchased 1,500 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $15.18 per share, for a total transaction of $22,770.00.
  • On Friday, December 16th, Snehal Patel purchased 1,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $13.01 per share, for a total transaction of $13,010.00.
  • On Friday, December 9th, Snehal Patel purchased 2,000 shares of Greenwich LifeSciences stock. The stock was acquired at an average cost of $13.11 per share, for a total transaction of $26,220.00.
  • On Friday, December 2nd, Snehal Patel bought 1,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $13.84 per share, for a total transaction of $13,840.00.
  • On Wednesday, November 2nd, Snehal Patel bought 2,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.79 per share, for a total transaction of $17,580.00.

Greenwich LifeSciences Stock Up 5.3 %

Shares of NASDAQ:GLSI opened at $18.38 on Tuesday. Greenwich LifeSciences, Inc. has a twelve month low of $6.82 and a twelve month high of $26.27. The stock’s 50 day moving average is $13.91 and its 200-day moving average is $10.96.

Greenwich LifeSciences (NASDAQ:GLSIGet Rating) last issued its earnings results on Monday, November 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Greenwich LifeSciences

Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in Greenwich LifeSciences by 150.2% during the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock worth $7,362,000 after buying an additional 225,213 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Greenwich LifeSciences during the second quarter worth $891,000. Millennium Management LLC bought a new stake in Greenwich LifeSciences during the second quarter worth $765,000. State Street Corp grew its holdings in Greenwich LifeSciences by 1.8% during the first quarter. State Street Corp now owns 66,485 shares of the company’s stock worth $1,304,000 after buying an additional 1,176 shares in the last quarter. Finally, Occudo Quantitative Strategies LP bought a new stake in Greenwich LifeSciences during the second quarter worth $199,000. Institutional investors own 6.18% of the company’s stock.

About Greenwich LifeSciences

(Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Articles

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.